AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 52 min read$BAX

BAX Maintained by Citigroup -- Price Target Lowered to $27.00

Citigroup maintained a Neutral rating for Baxter International (BAX) but lowered its price target to $27.00 from $28.00. Baxter's GF Value™ is $31.70, suggesting a 23.6% undervaluation, but the company is currently unprofitable with a P/S ratio of 8.47. Baxter's GF Score™ is 70/100, indicating moderate financial health and performance.

Original reporting
gurufocus.com
Published Oct 5, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BAX
Bearish
high confidence
Mentioned
$BAX
Relevance
6/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$BAXBearishMed
01

Why it matters

The analyst downgrade adds a fresh negative catalyst, likely prompting short‑term selling pressure.

02

Market read

Analyst price‑target revisions are a primary driver of short‑term equity moves, making this a medium‑value trading insight.

03

What to watch

Potential upside from upcoming product launches or contract wins not reflected in the target.

Relevance 6/10Novelty 6/10Timing: Oct 5 2026 release

Background

Baxter International is a $12.5 B market‑cap medical devices company with recent unprofitability and a high price‑to‑sales ratio.

Company-level read

Ticker impact

$BAXBearishHigh confidence
Context

Citigroup lowered its price target for Baxter International to $27.00, maintaining a Neutral rating, indicating a fresh analyst downgrade.

Expected impact

likely downside as investors price in the lower target

Evidence & confidence

Analyst price‑target cuts are a direct catalyst that often lead to short‑term price declines.

Market effects

Sector

The downgrade may weigh on the broader medical devices sector as peers are compared.

Regional

Limited to U.S. and European markets where Baxter trades.

Global

Modest; primarily affects investors tracking healthcare equipment stocks.

Counterpoint

What could challenge this read

Some investors may see the lower target as a buying opportunity given the stock's valuation discount.

Key entities

  • company
    Baxter International

    Medical devices and instruments manufacturer (ticker BAX).

  • analyst_firm
    Citigroup

    Equity research team led by Joanne Wuensch.

Read at source← All news

Related articles

SEP 2
$BAXLow

What Baxter International (BAX)'s CFO Transition Means For Shareholders

Baxter International (BAX) appointed John Rogers as CFO, with CEO Andrew Hider temporarily assuming CFO duties. Rogers brings cross-industry experience, potentially influencing capital allocation and reporting. Baxter aims for $12.4B revenue and $788.3M earnings by 2029, requiring 2.8% yearly revenue growth. The company recently launched a $600M tender offer for longer-dated notes, amending its credit agreement. Investors focus on margin stabilization and leverage.

simplywall.st3 min
AUG 21
$BAXLow

Baxter hires CFO from Smith & Nephew

Baxter named John Rogers as its new CFO, effective October 1. Rogers previously served as CFO of Smith & Nephew. Baxter's CEO, Andrew Hider, stated Rogers will aid in stabilizing the business and driving continuous improvement. Rogers' appointment follows Baxter's multiyear restructuring, including the sale of its biopharma and kidney care businesses. Baxter reiterated its 2026 financial outlook.

yahoo.com1 min
AUG 17
$BAXMed

Baxter’s interim CFO is leaving for Cardinal Health

Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

massdevice.com4 min
AUG 8
$BAXMedAI 8/10

Why Baxter International Stock Skyrocketed by 19% This Week

Baxter International shares rose about 19% this week after the company reported a Q2 earnings beat and raised full-year guidance, according to S&P Global Market Intelligence and Baxter. Q2 sales were $2.96B, up 5% year over year, and GAAP net income rose to $135M. Baxter now expects 2025 sales growth of 3% to 4% and adjusted EPS of $1.95 to $2.15.

aol.com4 min
AUG 1
$BAXMedAI 8/10

Why Baxter International Stock Skyrocketed by 19% This Week

Baxter International shares rose about 19% over the week after the company reported encouraging Q2 results. Baxter posted $2.96B revenue, up 5% year over year, and GAAP net income of $135M. Adjusted EPS was $0.56. Analysts expected $2.8B revenue and $0.37 adjusted EPS. Baxter raised FY guidance to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

fool.com3 min
JUL 31
$MSFTHighAI 8/10

Stocks Rally on Stellar Microsoft Earnings and Chip Stock Strength

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.

yahoo.com7 min